Company Overview and News

 
Cannabis Life Sciences Discusses the Benefits of Medical Marijuana with Uptick Newswire’s Stock Day Podcast and Addresses Its Potential Entry into The Massachusetts Market

2018-09-20 globenewswire
PHOENIX, Sept. 20, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) (CLS Holdings, Inc.), also known as Cannabis Life Sciences, does not want to lose sight of how its product can ultimately help people as they expand their market share. Jeffrey Binder, Chairman and Chief Executive Officer of CLS, tells Stock Day’s Everett Jolly there are many opportunities on the horizon.
MJNA CLSH CLSH]

 
CLS Holdings USA Executes Two Letters of Intent, which will provide the Opportunity to Enter the Rapidly Expanding Massachusetts Market

2018-09-17 globenewswire
LAS VEGAS, Sept. 17, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiaries, today announced it has executed two Letters of Intent (LOIs) to enter the rapidly growing Massachusetts market. CLS looks forward to the opportunity to enter the Massachusetts market, which has been operating as a legalized medical jurisdiction since 2015 and has approved legalized recreational use.
CLSH CLSH]

 
CLS Holdings USA Names Matthew Janz as VP of Marketing and Director of Operations at Oasis Cannabis

2018-08-21 globenewswire
LAS VEGAS, Aug. 21, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiary, today announced that Matthew Janz has joined the Company as VP of Marketing and Director of Operations at Oasis Cannabis.
CLSH CLSH]

 
CLS Holdings USA Closes $3 Million Investment from Navy Capital

2018-08-07 globenewswire
LAS VEGAS, Aug. 07, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiary, today announced the closing of a $3 million equity investment from Navy Capital Green International, Ltd., a cannabis-focused institutional fund based in New York City.
CLSH CLSH]

 
CLS Holdings USA Appoints Frank Tarantino, CPA as Chief Financial Officer

2018-07-27 globenewswire
LAS VEGAS, July 27, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) “CLS,” a diversified cannabis company operating as Cannabis Life Sciences and owner of an integrated cannabis producer and retailer in Nevada, is pleased to announce the appointment of Frank Tarantino as Chief Financial Officer.
CLSH CLSH]

3
CLS Holdings USA Closes Acquisition of Oasis Cannabis

2018-06-28 globenewswire
Enters the Legalized Cannabis Market in Las Vegas, NV Currently Generating Approximately $850,000 per Month in Revenue
CLSH CLSH]

3
Co-Founder & CEO of CLS Holdings USA, Inc. Jeffrey Binder Joins Everett Jolly on Uptick Newswire’s Stock Day Podcast

2018-05-31 globenewswire
PHOENIX, May 31, 2018 (GLOBE NEWSWIRE) -- Jeffrey Binder, Co-Founder, Chairman, and CEO of CLS Holdings USA, Inc (OTCQB:CLSH) (“CLS”, the “Company”) was recently interviewed about the company’s upcoming acquisition and other corporate matters on Uptick Newswire’s “Stock Day” podcast.
CLSH CLSH]

3
Snipp Signs MSA With CLS Holdings USA, Inc., to Implement a Customer Retention and Management Platform Across Its Future Portfolio of Cannabis Dispenseries

2018-05-23 globenewswire
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- Snipp Interactive Inc. ("Snipp" or the “Company”) (OTCQB:SNIPF) (TSX-V:SPN), a global provider of digital marketing promotions, rebates and loyalty solutions, today announced that it has signed a Master Services Agreement (“MSA”) with CLS HOLDINGS USA, (“CLS”) who is in the process of finalizing its purchase of Oasis Cannabis a "seed to sale" company focusing on Cultivation, Production and Dispensaries.
SNIPF CLSH SPN CLSH]

3
Snipp Signs MSA With CLS Holdings USA, Inc, to Implement a Customer Retention and Management Platform Across Its Future Portfolio of Dispensaries

2018-05-23 globenewswire
TORONTO, May 23, 2018 (GLOBE NEWSWIRE) -- Snipp Interactive Inc. ("Snipp" or the “Company”) (OTCQB:SNIPF) (TSX-V:SPN), a global provider of digital marketing promotions, rebates and loyalty solutions, today announced that it has signed a Master Services Agreement (“MSA”) with CLS HOLDINGS USA, (“CLS”) (OTCQB:CLSH), who is in the process of finalizing its purchase of Oasis Cannabis a "seed to sale" company focusing on Cultivation, Production and Dispensaries.
SNIPF CLSH SPN CLSH]

3
CLS Holdings USA, LLC Announces $10 Million Brokered Private Placement

2018-05-08 globenewswire
This is not an offer for sale, or solicitation of an offer to buy, in the United States or to any U.S. Person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended) of any equity shares or any other securities of the Company.
CLSH CLSH]

7
Trump Makes American Cannabis Great Again, say Eight Public Companies

2018-04-17 globenewswire - 1
LAS VEGAS, April 17, 2018 (GLOBE NEWSWIRE) -- Player’s Network, Inc. (OTCQB:PNTV), a publicly traded diversified holding company operating in marijuana, announced it has joined with eight publicly traded marijuana companies to applaud recent pronouncements from President Trump that he will support a legislative solution to protect states’ ability to regulate marijuana within their own borders.
MCIG MJNE MJVP MEDT NGTF CLSH CLSH]

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...